Claim Details

View detailed information about this claim and its related sources.

Back to Claims

Claim Information

Complete details about this extracted claim.

Claim Text: In 2025, the formula company ByHeart, whose products were linked to an infant botulism outbreak, shut down its Pennsylvania plant after inspectors found safety violations, including mold in a clean-water tank and dead insects in a production area.
Simplified Text: In 2025, formula company ByHeart shut down its Pennsylvania plant after its products were linked to an infant botulism outbreak and inspectors found safety violations.
Confidence Score: 1.000
Claim Maker: The author
Context Type: News Article
Context Details: { "year": "2025", "event": "Plant shutdown", "reason": "Linked to infant botulism outbreak, safety violations found by inspectors", "company": "ByHeart", "location": "Pennsylvania" }
Subject Tags: Health Business Safety
UUID: d6ec55a5-6059-4333-bb8a-ec4ca3648ed9
Vector Index: ✗ No vector
Created: September 18, 2026 at 2:01 AM (3 weeks ago)
Last Updated: September 18, 2026 at 2:01 AM (3 weeks ago)

Original Sources for this Claim (1)

All source submissions that originally contained this claim.

Screenshot of https://nytimes.com/2026/09/14/well/abbott-settlement-infant-formula.html

Abbott to Pay $385 Million to Settle Infant Formula Allegations

Completed News

12 claims 🔥

3 weeks ago

https://nytimes.com/2026/09/14/well/abbott-settlement-infant-formula.html

Abbott Laboratories will pay nearly $385 million to settle claims that it knowingly sold infant formula manufactured in facilities that did not meet safety requirements. This follows a 2022 recall linked to serious illnesses in babies and a nationwide formula shortage.

Infant Formula Abbott Laboratories Product Safety Recalls Justice Department Public Health

Similar Claims (5)

Other claims identified as semantically similar to this one.

In 2022, Abbott initiated a recall of powdered formulas manufactured at the plant, after federal health officials linked the products to four infants who were hospitalized with rare bacterial infectio... 1.000

Simplified: In 2022, Abbott recalled powdered formulas from its Sturgis plant after federal health officials linked them to four infants hospitalized with bacteri...

3 weeks ago
Production at the facility was halted, contributing to a nationwide formula shortage that lasted for months. 1.000

Simplified: The halting of production at Abbott's Sturgis facility contributed to a months-long nationwide formula shortage.

3 weeks ago
Abbott Laboratories, the maker of the popular infant formula Similac, will pay nearly $385 million to settle claims that it knowingly sold formula manufactured in facilities that did not meet safety r... 1.000

Simplified: Abbott Laboratories will pay nearly $385 million to settle claims of selling formula from facilities that did not meet safety requirements.

3 weeks ago
The federal government’s complaint detailed unsanitary conditions at the Michigan plant, including roof leaks, deteriorating equipment and inadequate cleaning procedures. 1.000

Simplified: A federal government complaint detailed unsanitary conditions at Abbott's Michigan plant, including roof leaks, deteriorating equipment, and inadequat...

3 weeks ago
In a 2022 consent decree reached with the Justice Department, Abbott agreed to replace the plant’s roof, address sanitation protocols and take other corrective steps, though it did not admit liability... 1.000

Simplified: In a 2022 consent decree with the Justice Department, Abbott agreed to replace its plant's roof and address sanitation, without admitting liability.

3 weeks ago